Clinical Trial Detail

NCT ID NCT02655822
Title Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Corvus Pharmaceuticals, Inc.

renal cell carcinoma

prostate adenocarcinoma


Atezolizumab + CPI-444


Age Groups: senior adult

No variant requirements are available.